首页> 外文期刊>Intensive care medicine >Propofol and remifentanil versus midazolam and fentanyl for sedation during therapeutic hypothermia after cardiac arrest: A randomised trial
【24h】

Propofol and remifentanil versus midazolam and fentanyl for sedation during therapeutic hypothermia after cardiac arrest: A randomised trial

机译:丙泊酚和瑞芬太尼与咪达唑仑和芬太尼用于心脏骤停后治疗性低温的镇静作用:一项随机试验

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To compare two protocols for sedation and analgesia during therapeutic hypothermia: midazolam and fentanyl versus propofol and remifentanil. The primary outcome was the time from discontinuation of infusions to extubation or decision not to extubate (offset time). Secondary outcomes were blood pressure, heart rate, use of vasopressors and inotropic drugs, pneumonia and neurological outcome. Methods: This was an open, randomised, controlled trial on 59 patients treated with therapeutic hypothermia (33-34 °C for 24 h) after cardiac arrest in two Norwegian university hospitals between April 2008 and May 2009. The intervention was random allocation to sedation and analgesia with propofol/remifentanil or midazolam/fentanyl. Results: Twenty-nine patients received propofol and remifentanil, and 30 midazolam and fentanyl. Baseline characteristics were similar. Sedation and analgesia were stopped in 35 patients, and extubation was performed in 17 of these. Sedation had to be continued for 24 patients. Time to offset was significantly lower in patients given propofol and remifentanil [mean (95 % confidence intervals) 13.2 (2.3-24) vs. 36.8 (28.5-45.1) h, respectively, p < 0.001]. Patients given propofol and remifentanil needed norepinephrine infusions twice as often (23 vs. 12 patients, p = 0.003). Incidence of pneumonia and 3-month neurological outcome were similar in the two groups. Conclusions: Time to offset was significantly shorter in patients treated with propofol and remifentanil. However, the clinical course in 40 % of patients prevented discontinuation of sedation and potential benefits from a faster recovery. The propofol and remifentanil group required norepinephrine twice as often, but both protocols were tolerated in most patients.
机译:目的:比较治疗性体温过低的两种镇静和镇痛方案:咪达唑仑和芬太尼与丙泊酚和瑞芬太尼。主要结果是从输液中断到拔管或决定不拔管的时间(偏移时间)。次要结果是血压,心率,使用血管加压药和正性肌力药物,肺炎和神经系统结果。方法:这是一项开放,随机,对照试验,研究对象是2008年4月至2009年5月在挪威两所大学医院心脏骤停后接受低温治疗(33-34°C,持续24 h)的59例患者。干预措施是随机分配镇静剂异丙酚/瑞芬太尼或咪达唑仑/芬太尼镇痛。结果:29例患者接受了异丙酚和瑞芬太尼,以及30例咪达唑仑和芬太尼。基线特征相似。 35例患者停止了镇静和镇痛作用,其中17例进行了拔管。 24名患者必须继续镇静。接受丙泊酚和瑞芬太尼的患者的抵消时间显着减少[平均值(95%置信区间)分别为13.2(2.3-24)小时和36.8(28.5-45.1)h,p <0.001]。接受丙泊酚和瑞芬太尼的患者需要两次去甲肾上腺素输注(23 vs. 12患者,p = 0.003)。两组的肺炎发生率和3个月的神经系统结局相似。结论:丙泊酚和瑞芬太尼治疗的患者抵消时间明显缩短。但是,在40%的患者中,临床过程阻止了镇静作用的中断,并避免了更快恢复的潜在益处。丙泊酚和瑞芬太尼组需要去甲肾上腺素的频率是两倍,但两种方案在大多数患者中都可以耐受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号